A Double-Blind, Randomized, Placebo-Controlled Phase 3 Study to Assess the Ef cacy and Safety of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Patients With Hypercortisolism Due to Cortisol-Secreting Adrenal Adenoma(s)/Hyperplasia